Clinical trials: Glial Tumor
Glioblastoma
Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen
Currently,6 cycles of Temozolomide adjuvant chemotherapy after concurrent radiotherapy and Temozolomide chemotherapy(STUPP regimen)for newly diagnosed postoperative GBM can increase the 2-year and 5-year overall survival rates of…
- Trial name
- NCT04547855
- Testing
- anlotinib combined with dose-dense temozolomide
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Yonggao Mou
Glioblastoma
Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients
The primary purpose of the study is to evaluate the efficacy and safety of supra-early post-surgery chemotherapy versus standard TEMODAL® regimen in treatment of patients with newly diagnosed glioblastoma multiforme.
- Trial name
- NCT02520635
- Testing
- supra-early TEMODAL® chemotherapy, standard TEMODAL® chemotherapy, Radiotherapy 60Gy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Beijing Tiantan Hospital
Glioblastoma Multiforme
Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)
Conduct a multicenter, open label Phase IIA trial of oral DCA in 40 surgical patients with recurrent GBM who have clinically indicated debulking surgery planned. No patients will be recruited at UF.
- Trial name
- NCT05120284
- Testing
- Dichloroacetate (DCA), Genotype
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Florida
Brain, Cancer
A Ketogenic Diet as a Complementary Treatment on Patients With High-grade Gliomas and Brain Metastases
The survival interval of patients with gliomas ranges between 12 to 15 months. Recent findings revealed that dietary interventions to reduce glucose and glycolytic pathways could have a therapeutic effect.
- Trial name
- NCT05564949
- Testing
- CKD
- Where
- 2 sites in Greece
- Volunteers
- 15 people
- Sponsor
- Attikon Hospital
Brain Tumor
Disease Progression and Treatment-induced Alterations in Glioblastoma
Summary of scientific evidence and rationale of this project: Integrative molecular-genetic approaches have provided important insights in the biology of glioblastoma.
- Trial name
- NCT02152748
- Testing
- analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Medical University of Vienna
Glioblastoma
Glioblastoma: Validation and Comparison Between Primary Tumor and Its Murine Model
Despite maximal safe surgery followed by combined chemo-radiation therapy, the outcome of patients suffering from glioblastoma (GBM) remains extremely poor with a median survival of 15 months.
- Trial name
- XENOGBM (NCT02904525)
- Testing
- 7 Tesla MRI, no contrast agent
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Andreas Hottinger
Glioblastoma (GBM)
Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma
The goal of this clinical trial is to test whether adding preventive intrathecal chemotherapy (thiotepa) to the standard Stupp regimen can lower the risk of leptomeningeal metastasis (LM) and extend survival in patients with…
- Trial name
- PRISM (NCT07511725)
- Testing
- Maximal surgical resection, Concomitant Chemoradiotherapy (Stupp backbone), Preventive Intrathecal Thiotepa
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Glioblastoma, Gliosarcoma
Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM
Primary objectives To determine maxi tolerated dose of Temodar® in combo w O6-benzylguanine administered for 5 consecutive days in pts w progressive/recurrent GBM To characterize toxicity associated w Temodar® in combo w O6-BG…
- Trial name
- NCT00612989
- Testing
- Temodar and O6-Benzylguanine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Duke University
Recurrent High Grade Glioma, Anaplastic Astrocytoma
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
Glioblastoma (GBM), WHO grade IV glioma, represents the majority of adult malignant primary brain tumors, with an incidence of 2-3 per 100,000 person-years.
- Conditions
- Recurrent High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma
- Trial name
- NCT05698524
- Testing
- PCI 24781, Temozolomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Nebraska
Glioma
Accelerating Motor Recovery in Glioma Patients Using Postoperative nrTMS
Project Name Clinical Research Protocol on Accelerating Motor Rehabilitation in Postoperative Motor-Deficient Glioma Patients Using nrTMS Research Objectives 1.
- Trial name
- NCT07285525
- Testing
- transcranial magnetic stimulation (TMS)
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Beijing Neurosurgical Institute
Glioblastoma, Recurrent Disease
Pilot Trial for Treatment of Recurrent Glioblastoma
This will be a single-arm open-label prospective pilot feasibility trial recruiting 10 adult patients with recurrent glioblastoma who are assigned to receive the personalized study treatment based on the genetic profile of their…
- Conditions
- Glioblastoma, Recurrent Disease, Recurrent Glioblastoma
- Trial name
- NCT05432518
- Testing
- Afatinib, Dasatinib, Palbociclib
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- AHS Cancer Control Alberta
Glioblastoma
Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery
A one time oral dose of ALA is taken before surgery. The medication makes the tumor visible under ultraviolet light which allow the surgeon to see more of the tumor for a more complete removal.
- Trial name
- NCT00961090
- Testing
- Aminolevulinic Acid
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Matthew R Quigley
Glioma, Brain Metastases
nTMS for Motor Mapping of Rolandic Lesions
To compare presurgical motor mapping by navigated transcranial magnetic stimulation for surgery (nTMS) of rolandic lesions to surgery with mapping without implementing these data into neuronavigation as control.
- Trial name
- Motorstim (NCT02879682)
- Testing
- nTMS data available for the surgeon, nTMS data not available for the surgeon
- Where
- 7 sites in Germany, Italy and 1 more
- Volunteers
- 330 people
- Sponsor
- Technical University of Munich
Malignant Melanoma, Medullary Thyroid Cancer
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
The primary objective of this study is to assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.
- Conditions
- Malignant Melanoma, Medullary Thyroid Cancer, Glioblastoma, Large-Cell Neuroendocrine Carcinoma
- Trial name
- NCT02709889
- Testing
- Rovalpituzumab tesirine, Dexamethasone
- Where
- 30 sites in United States
- Volunteers
- 200 people
- Sponsor
- AbbVie
Glioma
Study of GC101 TIL in Brain Glioma (Soochow2)
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with malignant glioma . Autologous TILs are expanded from tumor resections and infused i.v.
- Trial name
- NCT04943913
- Testing
- Tumor Infiltrating Lymphocytes (TIL)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Juncell Therapeutics
Glioblastoma Multiforme
Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS
This study aims to analyze the role the of Regorafenib in prolonging the Overall Survival of glioblastoma multiforme patients who progressed after surgery and a first-line chemo-radiotherapy treatment in the setting of "real…
- Trial name
- NCT04810182
- Testing
- Regorafenib 40 MG Oral Tablet [STIVARGA]
- Where
- 29 sites in Italy
- Volunteers
- 192 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Glioblastoma
A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma
This is an open-label, multicenter study to assess safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and preliminary efficacy of RO7428731 administered as a monotherapy in participants with newly…
- Trial name
- NCT05187624
- Testing
- RO7428731
- Where
- 8 sites in United States, Australia and 3 more
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Anaplastic Astrocytoma, Glioblastoma
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
In this multinational Phase III study the efficacy and safety of 10 µM AP 12009 is compared to standard chemotherapy (temozolomide or BCNU or CCNU) in adult patients with confirmed recurrent or refractory anaplastic astrocytoma…
- Trial name
- SAPPHIRE (NCT00761280)
- Testing
- trabedersen, temozolomide, Drug delivery system for administration of AP 12009
- Where
- 68 sites in United States, Argentina and 14 more
- Volunteers
- 27 people
- Sponsor
- Isarna Therapeutics GmbH
Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
This phase II trial tests how well retifanlimab with bevacizumab and hypofractionated radiotherapy, compared to bevacizumab and hypofractionated radiotherapy alone, works in treating patients with glioblastoma that has come back…
- Trial name
- NCT06160206
- Testing
- Bevacizumab, Biospecimen Collection, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 134 people
- Sponsor
- Academic and Community Cancer Research United
Glioblastoma
Tumor Electric Fields Treatment System for Glioblastoma
This early phase I trial will investigate the safety and feasibility of applying the Tumor Electric Fields Treatment System to subjects with recurrent glioblastoma.
- Trial name
- NCT04417933
- Testing
- Tumor Electric Fields Treatment System
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Xiangya Hospital of Central South University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.